Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PLEC | Q15149 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630992 | 0.80 | MEN1 (0.38) | PTGDR2NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL31394337 | 0.80 | NPC1 (0.33) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL30765098 | 0.80 | MEN1 (0.38) | PTGDR2NPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL30054448 | 0.79 | — | — | |
| SCHEMBL28928491 | 0.79 | — | — | |
| SCHEMBL24012991 | 0.78 | HDAC1 (0.34) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL31035586 | 0.78 | NPC1 (0.32) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL16396267 | 0.78 | SLC6A2 (0.32) | PTGDR2MAPK1HSD17B10MEN1ALDH1A1 | |
| SCHEMBL18578430 | 0.78 | NMT1 (0.32) | PTGDR2MAPK1HSD17B10MEN1ALDH1A1 | |
| SCHEMBL19792422 | 0.78 | NPC1 (0.32) | PTGDR2NPC1RAB9AMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12240815-B2 | Potent and selective human neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| CN-102666545-A | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | CELLZOME LTD | 2012-09-12 | — | — | CN | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | PTGDR2 134/4885NPC1 212/4885RAB9A 1611/4885 |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PTGDR2 985/4885NPC1 3936/4885RAB9A 1897/4885 |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | JAK1, JAK3, JAK2 | PTGDR2 942/4885NPC1 3856/4885RAB9A 1786/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | PTGDR2 134/4885NPC1 212/4885RAB9A 1611/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | PTGDR2 3987/4885NPC1 4269/4885RAB9A 2745/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | PTGDR2 3987/4885NPC1 4269/4885RAB9A 2745/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | PTGDR2 3987/4885NPC1 4269/4885RAB9A 2745/4885 |
| US-12240815-B2 | Potent and selective human neuronal nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | PTGDR2 223/4885NPC1 1520/4885RAB9A 2726/4885 |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | PTGDR2 223/4885NPC1 1520/4885RAB9A 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.